Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets genes by binding to the 3′-untranslated regions. They play vital roles in diverse biological processes, including the development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial role in the HF pathological process. MiRNAs involved in various biological process, such as differentiation, apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use in HF treatment.
Keywords: Non-coding RNA, microRNAs, hepatic fibrosis, hepatic stellate cells, biomarkers, therapy.
Current Pharmaceutical Design
Title:Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update
Volume: 27 Issue: 27
Author(s): Sai Zhu , Xin Chen, Yu Chen, Xiao-Feng Li, Si-Yu Chen, Juan-Juan Li , Ao Wang, Cheng Huang*Jun Li *
Affiliation:
- Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui,China
- Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui,China
Keywords: Non-coding RNA, microRNAs, hepatic fibrosis, hepatic stellate cells, biomarkers, therapy.
Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets genes by binding to the 3′-untranslated regions. They play vital roles in diverse biological processes, including the development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial role in the HF pathological process. MiRNAs involved in various biological process, such as differentiation, apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use in HF treatment.
Export Options
About this article
Cite this article as:
Zhu Sai , Chen Xin , Chen Yu , Li Xiao-Feng , Chen Si-Yu , Li Juan-Juan , Wang Ao , Huang Cheng*, Li Jun *, Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update, Current Pharmaceutical Design 2021; 27(27) . https://dx.doi.org/10.2174/1381612826666201023143542
DOI https://dx.doi.org/10.2174/1381612826666201023143542 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Pigment Epithelium-Derived Factor (PEDF) Augments Vascular Endothelial Growth Factor (VEGF)-Induced Recovery of Limb Perfusion after Ischemia in Klotho Mouse
Letters in Drug Design & Discovery Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Iontophoretic Mediated Intraarticular Delivery of Deformable Liposomes of Diclofenac Sodium
Current Drug Delivery Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets MicroRNA in Cervical Carcinogenesis: Window of Therapeutic Potential
Current Women`s Health Reviews p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Letters in Drug Design & Discovery Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal Cyclodextrin Inclusion Complexes Loaded in Particles as Drug Carrier Systems
Current Topics in Medicinal Chemistry Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry